Share on

MEA Solid Tumor Market Research Report – Segmented By Disease, Drugs and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2023 to 2028)

Published: March, 2023
ID: 6352
Pages: 145
Formats: report pdf report excel report power bi report ppt

MEA Solid Tumor Market (2023 to 2028)

The Solid Tumor Market in the Middle East and Africa is projected to rise at a steady CAGR during the forecast period.

There are fewer side effects, good therapy efficiency, and acceptable reimbursement schemes that are majorly driving the solid tumor market in this region. Around 8.2 million people died due to various cancers, as per the World Health Organization (WHO). This increasing incidence of cancer in the Middle East and Africa regions is a positive sign of the growth rate of the market. Drug approvals given by the U.S. FDA and favorable reimbursement policies for the solid tumor are further estimated to support the market growth in this region.

The costs associated with the treatments are so expensive, which is the primary inhibitor to market growth. Moreover, the costs associated with the R & D and strict administrative changes may impede the solid tumor market in Middle East & African during the forecast period.

This research report on the Middle East and Africa Solid Tumor Market has been segmented and sub-segmented into the following categories:

By Disease:

  • Breast cancer     
  • Lung cancer      
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Others    

By Drugs:

  • Carboplatin       
  • Cisplatin  
  • Gemcitabine      
  • Paclitaxel
  • Doxorubicin      
  • Bevacizumab     
  • Erlotinib  
  • Sunitinib  
  • Everolimus      
  • Docetaxel       
  • Abiraterone     
  • Abiraterone acetate     
  • Cabazitaxel

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regional Analysis:

The MEA solid tumor was accounted for the least share in the global market in 2019 among all the regions but expected to rise at a steady rate during the forecast period. UAE is expected to dominate the MEA solid tumor market with the highest share between 2020 to 2025. It is likely to develop different measures to bring out cancer awareness among the public and the treatment. The rising advent of medical tourism and the rise in medical expenditure present growth opportunities for the market. Also, the market key players' considerable investments in research and development for manufacturing drugs and advanced technologies in treatments like Herceptin are likely to flourish the market growth in the region. Moreover, other region countries are accounted to have a substantial increase in the region in the upcoming years throughout the period.

Notable companies leading the MEA Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample